Using antisense technology to develop a novel therapy for α-1 antitrypsin deficient (AATD) liver disease and to model AATD lung disease

References

• EkeowaUI, GooptuB, BelorgeyD, HägglöfP, Karlsson-LiS, MirandaE, PérezJ, MacLeodI, KrogerH, MarciniakSJ, et al. alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. Clin Sci (Lond)2009; 116:837 - 50; http://dx.doi.org/10.1042/CS20080484; PMID: 19426146
   PubMed Web of Science ®Google Scholar
• FairbanksKD, TavillAS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol2008; 103:2136 - 41, quiz 2142; http://dx.doi.org/10.1111/j.1572-0241.2008.01955.x; PMID: 18796107
   PubMed Web of Science ®Google Scholar
• FregoneseL, StolkJ. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis2008; 3:16; http://dx.doi.org/10.1186/1750-1172-3-16; PMID: 18565211
   PubMed Web of Science ®Google Scholar
• JanciauskieneSM, BalsR, KoczullaR, VogelmeierC, KöhnleinT, WelteT. The discovery of α1-antitrypsin and its role in health and disease. Respir Med2011; 105:1129 - 39; http://dx.doi.org/10.1016/j.rmed.2011.02.002; PMID: 21367592
   PubMed Web of Science ®Google Scholar
• LaurellCB, ErikssonS. The electrophoretic α1-globulin pattern of serum in α1-antitrypsin deficiency. 1963. COPD2013; 10:Suppl 13 - 8; http://dx.doi.org/10.3109/15412555.2013.771956; PMID: 23527532
   PubMedGoogle Scholar
• StockleyRA, MiravitllesM, VogelmeierC, Alpha One International Registry (A.I.R.). Augmentation therapy for alpha-1 antitrypsin deficiency: towards a personalised approach. Orphanet J Rare Dis2013; 8:149; http://dx.doi.org/10.1186/1750-1172-8-149; PMID: 24063809
   PubMed Web of Science ®Google Scholar
• ErikssonS, CarlsonJ, VelezR. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med1986; 314:736 - 9; http://dx.doi.org/10.1056/NEJM198603203141202; PMID: 3485248
   PubMed Web of Science ®Google Scholar
• LomasDA, EvansDL, FinchJT, CarrellRW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature1992; 357:605 - 7; http://dx.doi.org/10.1038/357605a0; PMID: 1608473
   PubMed Web of Science ®Google Scholar
• RudnickDA, PerlmutterDH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. Hepatology2005; 42:514 - 21; http://dx.doi.org/10.1002/hep.20815; PMID: 16044402
   PubMed Web of Science ®Google Scholar
• TeckmanJH, LindbladD. Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management. Curr Gastroenterol Rep2006; 8:14 - 20; http://dx.doi.org/10.1007/s11894-006-0059-8; PMID: 16510030
   PubMedGoogle Scholar
• AliR, PerfumoS, della RoccaC, AmiconeL, PozziL, McCullaghP, Millward-SadlerH, EdwardsY, PoveyS, TripodiM. Evaluation of a transgenic mouse model for alpha-1-antitrypsin (AAT) related liver disease. Ann Hum Genet1994; 58:305 - 20; http://dx.doi.org/10.1111/j.1469-1809.1994.tb00728.x; PMID: 7864587
   PubMedGoogle Scholar
• CarlsonJA, RogersBB, SifersRN, FinegoldMJ, CliftSM, DeMayoFJ, BullockDW, WooSL. Accumulation of PiZ alpha 1-antitrypsin causes liver damage in transgenic mice. J Clin Invest1989; 83:1183 - 90; http://dx.doi.org/10.1172/JCI113999; PMID: 2784798
   PubMed Web of Science ®Google Scholar
• DycaicoMJ, GrantSG, FeltsK, NicholsWS, GellerSA, HagerJH, PollardAJ, KohlerSW, ShortHP, JirikFR, et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. Science1988; 242:1409 - 12; http://dx.doi.org/10.1126/science.3264419; PMID: 3264419
   PubMed Web of Science ®Google Scholar
• RütherU, TripodiM, CorteseR, WagnerEF. The human alpha-1-antitrypsin gene is efficiently expressed from two tissue-specific promotors in transgenic mice. Nucleic Acids Res1987; 15:7519 - 29; http://dx.doi.org/10.1093/nar/15.18.7519; PMID: 3498933
   PubMedGoogle Scholar
• Kushi A, Akiyama K, Noguchi M, Edamura K, Yoshida T, Sasai H. Disruption of the murine alpha1-antitrypsin/PI2 gene. Experimental animals / Japanese Association for Laboratory Animal Science 2004; 53:437-43.
   Google Scholar
• WangD, WangW, DawkinsP, PatersonT, KalshekerN, SallenaveJM, HoughtonAM. Deletion of Serpina1a, a murine α1-antitrypsin ortholog, results in embryonic lethality. Exp Lung Res2011; 37:291 - 300; http://dx.doi.org/10.3109/01902148.2011.554599; PMID: 21574874
   PubMed Web of Science ®Google Scholar
• MartoranaPA, BrandT, GardiC, van EvenP, de SantiMM, CalzoniP, MarcolongoP, LungarellaG. The pallid mouse. A model of genetic alpha 1-antitrypsin deficiency. Lab Invest1993; 68:233 - 41; PMID: 8441253
   PubMed Web of Science ®Google Scholar
• YoshidaM, SakiyamaS, KenzakiK, TobaH, UyamaK, TakehisaM, KondoK, TangokuA. Functional evaluation of pallid mice with genetic emphysema. Lab Invest2009; 89:760 - 8; http://dx.doi.org/10.1038/labinvest.2009.34; PMID: 19381131
   PubMedGoogle Scholar
• BennettCF, SwayzeEE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol2010; 50:259 - 93; http://dx.doi.org/10.1146/annurev.pharmtox.010909.105654; PMID: 20055705
   PubMed Web of Science ®Google Scholar
• GuoS, BootenSL, AghajanM, HungG, ZhaoC, BlomenkampK, GattisD, WattA, FreierSM, TeckmanJH, et al. Antisense oligonucleotide treatment ameliorates alpha-1 antitrypsin-related liver disease in mice. J Clin Invest2014; 124:251 - 61; http://dx.doi.org/10.1172/JCI67968; PMID: 24355919
   PubMed Web of Science ®Google Scholar
• PerlmutterDH, ColeFS, KilbridgeP, RossingTH, ColtenHR. Expression of the alpha 1-proteinase inhibitor gene in human monocytes and macrophages. Proc Natl Acad Sci U S A1985; 82:795 - 9; http://dx.doi.org/10.1073/pnas.82.3.795; PMID: 3871944
   PubMed Web of Science ®Google Scholar
• HeitC, JacksonBC, McAndrewsM, WrightMW, ThompsonDC, SilvermanGA, NebertDW, VasiliouV. Update of the human and mouse SERPIN gene superfamily. Hum Genomics2013; 7:22; http://dx.doi.org/10.1186/1479-7364-7-22; PMID: 24172014
   PubMed Web of Science ®Google Scholar
• StollerJK, AboussouanLS. Alpha1-antitrypsin deficiency. Lancet2005; 365:2225 - 36; http://dx.doi.org/10.1016/S0140-6736(05)66781-5; PMID: 15978931
   PubMed Web of Science ®Google Scholar
• BootsAW, GerloffK, BartholoméR, van BerloD, LedermannK, HaenenGR, BastA, van SchootenFJ, AlbrechtC, SchinsRP. Neutrophils augment LPS-mediated pro-inflammatory signaling in human lung epithelial cells. Biochim Biophys Acta2012; 1823:1151 - 62; http://dx.doi.org/10.1016/j.bbamcr.2012.04.012; PMID: 22575681
   PubMedGoogle Scholar
• GooptuB, DickensJA, LomasDA. The molecular and cellular pathology of alpha-antitrypsin deficiency. Trends Mol Med2013; http://dx.doi.org/10.1016/j.molmed.2013.10.007; PMID: 24374162
   PubMedGoogle Scholar
• StockleyRA, TurnerAM. alpha-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends Mol Med2013; http://dx.doi.org/10.1016/j.molmed.2013.11.006; PMID: 24380646
   PubMedGoogle Scholar
• TeckmanJH, JainA. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep2014; 16:367; http://dx.doi.org/10.1007/s11894-013-0367-8; PMID: 24338605
   PubMedGoogle Scholar
• ClarkVC, DhanasekaranR, BrantlyM, RouhaniF, SchreckP, NelsonDR. Liver test results do not identify liver disease in adults with α(1)-antitrypsin deficiency. Clin Gastroenterol Hepatol2012; 10:1278 - 83; http://dx.doi.org/10.1016/j.cgh.2012.07.007; PMID: 22835581
   PubMed Web of Science ®Google Scholar
• TeckmanJH. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD2013; 10:Suppl 135 - 43; http://dx.doi.org/10.3109/15412555.2013.765839; PMID: 23527737
   PubMedGoogle Scholar
• LomasDA. The selective advantage of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med2006; 173:1072 - 7; http://dx.doi.org/10.1164/rccm.200511-1797PP; PMID: 16439713
   PubMed Web of Science ®Google Scholar
• SvegerT. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand1988; 77:847 - 51; http://dx.doi.org/10.1111/j.1651-2227.1988.tb10767.x; PMID: 2905108
   PubMed Web of Science ®Google Scholar
• ClancyJ, TurnerC. Smoking and COPD: the impact of nature-nurture interactions. Br J Nurs2013; 22:820 - , 822-6; PMID: 24260992
   PubMedGoogle Scholar
• DickensJA, LomasDA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther2011; 5:391 - 405; PMID: 21966212
   PubMed Web of Science ®Google Scholar